NasdaqGS - Nasdaq Real Time Price USD

AN2 Therapeutics, Inc. (ANTX)

1.2000

-0.0200

(-1.64%)

At close: May 9 at 4:00:02 PM EDT

1.2100

+0.01

+(0.83%)

After hours: May 9 at 5:57:27 PM EDT

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

MENLO PARK, Calif., May 01, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced topline results from the Phase 3 portion of the EBO-301 study evaluating epetraborole on top of an optimized background regimen (EBO+OBR) in treatment-refractory MAC lung disease.

Business Wire 8 days ago

ANTX
-1.64%
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

MENLO PARK, Calif., April 30, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.

Business Wire 10 days ago

ANTX
-1.64%
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. last month

ANTX
-1.64%
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., March 25, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024.

Business Wire last month

ANTX
-1.64%
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

MENLO PARK, Calif., March 03, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference.

Business Wire 2 months ago

ANTX
-1.64%
Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring

As the S&P 500 and Nasdaq Composite continue to experience declines, investor sentiment is being tested by economic uncertainties and fluctuating market conditions. Despite these challenges, penny stocks remain a notable segment for investors seeking opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, it still encapsulates firms that have the potential for growth when backed by strong financials. In this context, certain penny stocks are emerging as...

Simply Wall St. 2 months ago

ANTX
-1.64%

GSUN

NTWK
$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

MENLO PARK, Calif., February 24, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO) instrument as the primary efficacy endpoint for the Phase 3 part of the EBO-301 trial. The C

Business Wire 2 months ago

ANTX
-1.64%
AN2 Therapeutics to Participate at Upcoming Investor Conferences

MENLO PARK, Calif., February 20, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March.

Business Wire 2 months ago

ANTX
-1.64%
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MENLO PARK, Calif., January 29, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

Business Wire 3 months ago

ANTX
-1.64%
Favourable Signals For AN2 Therapeutics: Numerous Insiders Acquired Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 3 months ago

ANTX
-1.64%
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when...

Simply Wall St. 5 months ago

IMRX

WDH

ANTX
-1.64%
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

MENLO PARK, Calif., November 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial.

Business Wire 5 months ago

ANTX
-1.64%
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

MENLO PARK, Calif., October 17, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.

Business Wire 6 months ago

ANTX
-1.64%
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MENLO PARK, Calif., August 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Business Wire 8 months ago

ANTX
-1.64%
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Zacks 8 months ago

ANTX
-1.64%

ARCT

FULC
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

MENLO PARK, Calif., August 16, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025.

Business Wire 8 months ago

ANTX
-1.64%
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., August 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024.

Business Wire 8 months ago

ANTX
-1.64%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 8 months ago

ANTX
-1.64%

TLS
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce

On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in treatment-refractory mycobacterium avium complex (MAC) lung disease. The Phase 2 part of the study met its primary objective of demonstrating the potential validation of a novel patient-reported outcome (PRO) tool and a higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. pla

Benzinga 8 months ago

ANTX
-1.64%
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Pharmaceutical Technology 8 months ago

ANTX
-1.64%

Performance Overview

Return	ANTX	S&P 500 (^GSPC)
YTD	-13.04%	-3.77%
1-Year	-51.42%	+8.55%
3-Year	-92.06%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Favourable Signals For AN2 Therapeutics: Numerous Insiders Acquired Stock

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Top Midday Decliners

Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

Performance Overview